Forbes June 16, 2022
Bruce Japsen

Walgreens is launching a clinical trial business, hoping to increase racial and ethnic diversity for patients in drug research.

Walgreens effort in clinical trials comes as the U.S. Food and Drug Administration and the Biden White House look to improve drug research and patient health outcomes by enrolling more Americans from underrepresented racial and ethnic populations into U.S. clinical trials.

The FDA has acknowledged that racial and ethnic minorities are “frequently underrepresented in biomedical research,” the agency said two months ago when outlining the government’s steps to improve diversity in clinical trials given an estimated one in five drugs have varied responses in ethnic groups yet most clinical trial participants are white.

For its part, Walgreens said it will be...

Today's Sponsors

Oliver Wyman
Patient Bond
pCare

Today's Sponsors

Amwell
Oliver Wyman

Today's Sponsor

Patient Bond

 
Topics: Clinical Trials, FDA, Govt Agencies, Pharma, Pharma / Biotech, Trends
Accelerate Cures Through International Collaboration In Clinical Trials: Cancer Moonshot Pathways
Keep Our Foot on the Gas for Clinical Trial Diversity
Building a global supply chain network for clinical trial products
Connecting EHR to clinical trials: How to embrace the promise of real-world data
Opinion: Lack of diversity in clinical trials costs billions of dollars. Incentives can spur innovation